

PUBLIC SUMMARY DOCUMENT

Product: Omnigon Biotrol Petite
Applicant: Omnigon
Date of SPAP Meeting: 28 April 2020

1. Proposed Deletion on the Stoma Appliance Scheme

The applicant, Omnigon, sought the deletion of the entire product range from the current listing of the Omnigon Biotrol Petite (SAS Code 3791M) in subgroup 1(a) of the Stoma Appliance Scheme (SAS) Schedule. The product, including two variants, is currently listed at a unit price of \$1.373, with a maximum monthly quantity of 60 units.

2. Substitute products

The nominated substitute product is the Omnigon Welland Aurum (SAS Code 80092J). The product is currently listed in subgroup 1(a) of the SAS Schedule at a unit price of \$1.373, with a maximum monthly quantity of 60 units.

Variants to be deleted

Product Code	Description
F00011	opaque with fabric cover on both sides, cap, 100ml, hydrocolloid baseplate, flat, self-adhesive, standard wear, square, cut-to-fit, 15mm, 35mm.
F00015	opaque with fabric cover on both sides, cap, 100ml, hydrocolloid baseplate, flat, self-adhesive, standard wear, oblong, pre-cut, 35mm.

Nominated substitute – SAS Code 80092J – Omnigon Welland Aurum

Product Code	Description
XMHSS513	Opaque with fabric cover on both sides, extra small, 1.3mm, hydrocolloid baseplate with Manuka Honey self-adhesive, standard wear, oval, cut-to-fit, 13mm.

3. Background

This product was first listed on the SAS Schedule in January 2013.

4. Clinical Place for the Product

The proposed product provides an alternative for users requiring a one-piece closed pouch with stoma cap.

Financial Analysis

The deletion of the entire product range is recommended. Substitute products are currently listed in subgroup 1(a) of the SAS Schedule at the same cost and maximum monthly quantity. It is therefore unlikely that there would be any budgetary impact for the SAS as a consequence of deleting this product.

5. Panel Recommendation

The Panel recommended the deletion of the entire product range for Omnigon Biotrol Petite (SAS Code 3791M) listed in subgroup 1(a) of the SAS Schedule at the unit price of \$1.373, with a maximum monthly quantity of 60 units.

The Panel also noted that Omnigon is to advise Stoma Associations, ostomates, Stomal Therapy Nurses and ACSA of the deletion. A period of approximately six months from the Panel recommended date (28 April 2020) should be given to allow users of the product to seek a suitable alternative and to enable Stoma Associations to manage their stock levels.

6. Context for Decision

The Panel helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. A Panel decision not to recommend listing or changes to a listing does not represent a final Panel view about the merits of a particular stoma product. A company can resubmit to the Panel following a decision not to recommend listing or changes to a listing. The Panel is an advisory committee and as such its recommendations are non-binding on Government. All Panel recommendations are subject to Cabinet/Ministerial approval.

7. Applicant's Comment

Omnigon agrees with the Panel's recommendation.